ArticleOncogene2017
Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53.
Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 56 citations in OpenAlex.
- Deciphering the molecular crosstalk between type 2 diabetes and pancreatic cancer through cross-disease co-expression network analysis.Biochemistry and biophysics reports · 2026Article
- Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition.Journal for immunotherapy of cancer · 2026Article
- Exploring the genetic link between gastroesophageal reflux disease and pancreatic cancer: insights from Mendelian randomization.BMC cancer · 2025Article
- Selective epithelial expression of KRASScientific reports · 2025Article
- Inflammation and cancer: molecular mechanisms and clinical consequences.Frontiers in oncology · 2025Review
- Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer.Science (New York, N.Y.) · 2024Article
- Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.Frontiers in immunology · 2024Review
- Review
- Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma.Molecular cancer · 2023Review
- Focus on Therapeutic Options for Surgically Resectable Pancreatic Adenocarcinoma Based on Novel Biomarkers.Current oncology (Toronto, Ont.) · 2023Review
- Review
- The Role of Microbiota in Pancreatic Cancer.Cancers · 2023Review
- The Role of Krüppel-like Factors in Pancreatic Physiology and Pathophysiology.International journal of molecular sciences · 2023Review
- Clonal hematopoiesis and bone marrow inflammation.Translational research : the journal of laboratory and clinical medicine · 2023Review
- Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation.Current issues in molecular biology · 2023Article
- Focusing on Hippo Pathway in Stem Cells of Oral Origin, Enamel Formation and Periodontium Regeneration.Organogenesis · 2022Article
- Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy.Cancer communications (London, England) · 2022Review
- Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.Disease models & mechanisms · 2022Article
- Cancer-inducing niche: the force of chronic inflammation.British journal of cancer · 2022Review
- Connecting the Human Microbiome and Pancreatic Cancer.Cancer metastasis reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 3 countries.
Funding
Abstract
Chronic inflammation (CI) is a risk factor for pancreatic cancer (PC) including the most common type, ductal adenocarcinoma (PDAC), but its role and the mechanisms involved are unclear. To investigate the role of CI in PC, we generated genetic mouse models with pancreatic specific CI in the presence or absence of TP53. Mice were engineered to express either cyclooxygenase-2 (COX-2) or IκB kinase-2 (IKK2), and TP53
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.